biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
Vir Biotechnology clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
Vir Biotechnology projects
7 ClinicalTrials.gov programs sponsored by Vir Biotechnology.
Vir Biotechnology has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
LY3819253
Vir Biotechnology
Covid19
1 trial -
Tobevibart
Vir Biotechnology
Viral Hepatitis
3 trials -
VIR-3434, VIR-2218
Vir Biotechnology
Chronic Hepatitis D Virus (HDV) Infection
1 trial -
VIR-7831
Vir Biotechnology
COVID-19
1 trial -
VIR-7831 (sotrovimab)
Vir Biotechnology
Covid19
1 trial -
VIR-CHDV-V205
Vir Biotechnology
Chronic Hepatitis D Virus (HDV) Infection
1 trial -
sotrovimab
Vir Biotechnology
Covid19
3 trials
Frequently asked questions
How many clinical projects does Vir Biotechnology have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.